Skip to main content
TipRanks
Go Ultimate75% OFF

Venus Remedies Limited (VENUSREM) AI Stock Analysis

1 Followers
IN:VENUSREM

Venus Remedies Limited

(NSE:VENUSREM)

Select Model
Rating:69Neutral
Price Target:INR 1,666.00â–²(9.50% Upside)
Action:downgraded
Date:10/31/26

Strong financial performance is the primary support, reinforced by reasonable valuation. However, the stock is trading below all major moving averages with negative MACD, making weak technical momentum the main constraint on the overall score.

Positive Factors
Revenue GrowthA return to sustained revenue growth across the latest three years indicates improving commercial traction after the 2023 decline. Continued top-line expansion can support operating leverage, strengthen scale in hospital-focused markets, and provide a foundation for durable earnings growth.
Negative Factors
Uncertain Margin SustainabilityThe latest profit surge is encouraging, but fluctuating gross margins make it harder to determine how much of the improvement is structurally repeatable. Without clear 2026 margin detail, future earnings durability remains less certain if profitability normalizes.

Venus Remedies Limited (VENUSREM) vs. iShares MSCI India ETF (INDA)

-50%0%50%100%150%200%IN:VENUSREM+121.65%INDA-5.34%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
INR 21.03B
Dividend Yield
0.64%
Average Volume (3M)
3,618
Price to Earnings (P/E)
17.1
Beta (1Y)
0.96
Revenue Growth
20.22%
EPS Growth
73.03%
Country
India
Employees
1,472
Sector
General
Sector Strength
55
Industry
Drug Manufacturers - Specialty & Generic

Venus Remedies Limited Business Overview & Revenue Model

Company Description

Venus Remedies Limited is a pharmaceutical enterprise engaged in the development, production, and global distribution of its medicinal products, serving both the Indian and international markets. The company's diverse portfolio addresses a wide spect...

Venus Remedies Limited Financial Statement Overview

Summary

Strong revenue and profit growth, improved margins, very low leverage, and better operating and free cash flow support a robust financial profile. Historical volatility in growth and cash generation limits the score.

Income Statement

86Very Positive

Balance Sheet

90Very Positive

Cash Flow

82Very Positive
Financial statement breakdown
BreakdownTTMMar 2026Mar 2025Mar 2024Mar 2023Mar 2022
Income Statement
Total Revenue8.37B7.70B6.48B5.91B5.56B5.99B
Gross Profit3.16B2.68B1.66B2.18B2.25B2.00B
EBITDA1.85B1.60B944.10M711.80M703.46M701.40M
Net Income1.22B1.03B453.20M284.91M265.70M407.24M
Balance Sheet
Total Assets8.40B8.54B7.16B6.27B6.01B5.80B
Cash, Cash Equivalents and Short-Term Investments901.50M1.04B1.64B838.05M720.77M432.56M
Total Debt117.40M124.10M16.90M413.25M422.90M428.45M
Total Liabilities1.35B1.90B1.55B1.39B1.41B1.39B
Stockholders Equity7.05B6.64B5.61B4.88B4.60B4.40B
Cash Flow
Free Cash Flow01.20B812.90M278.40M288.02M272.94M
Operating Cash Flow01.57B909.20M372.85M366.20M410.01M
Investing Cash Flow0-1.84B-807.90M-72.09M-508.30M-166.26M
Financing Cash Flow0-25.30M-9.50M-10.83M-5.70M-94.77M

Venus Remedies Limited Technical Analysis

Technical Analysis SentimentPositive
Last Price1521.50

Price Trends

50DMA1560.36Negative
100DMA1628.22Negative
200DMA1314.23Positive

Market Momentum

MACD-24.81Negative
RSI57.08Neutral
STOCH86.18Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:VENUSREM, the sentiment is Positive. The current price of 1521.50 is above the 20-day moving average (MA) of 1427.96, below the 50-day MA of 1560.36, and above the 200-day MA of 1314.23, indicating a neutral trend. The MACD of -24.81 indicates Negative momentum. The RSI at 57.08 is Neutral, neither overbought nor oversold. The STOCH value of 86.18 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for IN:VENUSREM.

Venus Remedies Limited Peers Comparison

Overall Rating

UnderperformOutperform
Sector (55)

Financial Indicators

IN:VENUSREM against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
IN:VENUSREMIN:VENUSREM69NeutralINR 20.83B17.14―0.64%20.22%73.03%
IN:SYNCOMFIN:SYNCOMF69NeutralINR 19.83B23.29―0.47%0.44%48.60%
IN:LINCOLNIN:LINCOLN67NeutralINR 10.50B10.77―0.34%14.25%21.11%
IN:WINDLASIN:WINDLAS66NeutralINR 20.17B30.54―0.64%18.48%-0.41%
Sector *55Neutral$6.65B3.83-15.92%6.20%10.91%7.18%
IN:INDSWFTLABIN:INDSWFTLAB51NeutralINR 30.41B35.76――66.39%-72.31%
IN:INDOCOIN:INDOCO50NeutralINR 20.95B66.81―0.09%10.75%―

* General Sector Average

Performance Comparison

0%100%200%300%IN:VENUSREMIN:INDOCOIN:INDSWFTLABIN:LINCOLNIN:SYNCOMFIN:WINDLASDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
IN:VENUSREM and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
IN:VENUSREMVenus Remedies Limited1521.50879.63137.04%
IN:INDOCOIndoco Remedies Limited224.60-37.87-14.43%
IN:INDSWFTLABInd-Swift Laboratories Ltd.332.50236.90247.80%
IN:LINCOLNLincoln Pharmaceuticals Ltd519.95-13.74-2.57%
IN:SYNCOMFSyncom Formulation (India) Ltd.20.904.8830.45%
IN:WINDLASWindlas Biotech Ltd.998.70189.6723.44%

Venus Remedies Limited Corporate Events

Venus Remedies Secures Shareholder Approval for All Resolutions at 37th AGM

Aug 21, 2026

Venus Remedies Limited has announced that all 12 resolutions proposed at its 37th Annual General Meeting, held on August 20, 2026 via video conferencing, were approved by the requisite majority under SEBI listing regulations and the Companies Act. Th...

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Sep 06, 2026